HAMLET TO4 B — HAMLET Pharma AB Share Price
Last trade - 00:00- SEK261.96m
- SEK222.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.89 | ||
| Price to Tang. Book | 6.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.04% | ||
| Return on Equity | -84.36% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hamlet Pharma AB is a Sweden-based company that develops cancer therapeutics. The Company develops cancer therapeutics based on research into protein complexes that selectively induce cell-death in tumours. HAMLET, which stands for Human Alpha-lactalbumin Made LEthal to Tumours, is a protein-fatty acid complex derived from human milk. The complex induces apoptosis in tumour cells while leaving normal cells unaffected. In laboratory experiments, HAMLET is active against many different types of tumour cells, and uses several mechanisms to trigger cell death. HAMLET is also being evaluated clinically on skin papillomas and on bladder cancers. Alpha1H is a Company’s drug candidate for bladder cancer in ongoing phase I/II clinical trials.
Directors
- Catharina Svanborg CHM
- Mats Persson CEO (58)
- Bill Hansson DRC
- Christer Kohler DRC (72)
- Helena Lomberg DRC
- Bengt Westermark DRC (74)
- Last Annual
- June 30th, 2022
- Last Interim
- June 30th, 2022
- Incorporated
- January 1st, 1970
- Public Since
- October 23rd, 2015
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 110,529,666
- Address
- Klinikgatan 32, LUND, 222 42
- Web
- https://hamletpharma.com/
- Phone
- +46 40122500
- Auditors
- Ernst & Young AB
Similar to HAMLET TO4 B
Abera Bioscience AB
AktieTorget Stock Exchange
Aptahem AB
AktieTorget Stock Exchange
Arcede Pharma AB
AktieTorget Stock Exchange
Carbiotix AB (publ)
AktieTorget Stock Exchange
Cereno Scientific AB
AktieTorget Stock Exchange
FAQ
As of Today at 01:09 UTC, shares in HAMLET Pharma AB are trading at SEK0.14. This share price information is delayed by 15 minutes.
Shares in HAMLET Pharma AB last closed at SEK0.14 and the price had moved by -90.67% over the past 365 days. In terms of relative price strength the HAMLET Pharma AB share price has underperformed the FTSE Global All Cap Index by -91.04% over the past year.
There is no consensus recommendation for this security.
HAMLET Pharma AB does not currently pay a dividend.
HAMLET Pharma AB does not currently pay a dividend.
HAMLET Pharma AB does not currently pay a dividend.
To buy shares in HAMLET Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.14, shares in HAMLET Pharma AB had a market capitalisation of SEK261.96m.
Here are the trading details for HAMLET Pharma AB:
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: HAMLET TO4 B
Based on an overall assessment of its quality, value and momentum HAMLET Pharma AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HAMLET Pharma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -86.02%.
As of the last closing price of SEK0.14, shares in HAMLET Pharma AB were trading -86.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HAMLET Pharma AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
HAMLET Pharma AB's management team is headed by:
- Catharina Svanborg - CHM
- Mats Persson - CEO
- Bill Hansson - DRC
- Christer Kohler - DRC
- Helena Lomberg - DRC
- Bengt Westermark - DRC